Dear Editor, Hereditary spastic paraplegia (HSP) refers to a group of familial diseases that are characterized by progressive degeneration of the corticospinal tracts. Clinically, they present with gradually increasing lower limb spasticity and weakness, usually over many years after onset. Prevalence is low at about 3 to 10/100,000.[1] Classification of HSP is increasingly based upon genetics, as there is phenotypic heterogeneity of HSP within the same family harboring the same genetic defect. The genetic classification of HSP is based upon mode of inheritance, chromosomal locus, and causative mutation. The genetic loci are designated as SPG (for "Spastic Paraplegia") and are numbered sequentially based on the order of locus discovery. HSP-76 is an autosomal recessive neurological disorder.[2] It is characterized by onset of slowly progressive spasticity of the lower limbs in young adults. We evaluated a family of 8 affected individuals hailing from Belgaum District in Karnataka State, India, in the Neurology Out-Patient Clinic of our Institute. The proband was a 30-year-old male, who was apparently normal till the age of 22 years. The first symptom he noticed was a tendency to drag his left lower limb while walking. Later, he noticed that his left lower limb would cross in front of his right while walking, resulting in slowness and change in his gait while walking. Over a period of few months, he started tripping over small obstacles. Gradually the symptoms appeared in his right lower limb, with slow progression. He developed progressive stiffness and weakness of both lower limbs with reduced range of movements at the joints. Initially, he had no difficulty in getting up from squatting position or buckling of knees. He never had symptoms in his upper limbs and no incoordination, sensory, cognitive, or sphincter disturbances. Over a period of years, the patient gradually developed dysarthria, while his lower limb symptoms progressed for a while and subsequently plateaued. The patient was able to perform his activities of daily living on his own with difficulty and remained independent and ambulant without assistance. Detailed family history revealed that multiple members of his family were affected [Figure 1]. The patient was born to a consanguineous marriage, and he was the third born child. His sibling brother is affected, while his sister is not. There are also several affected members in his extended family.Figure 1: Pedigree Chart, with patients numbered serially from first-generation (Proband is patient number 17)Higher mental functions including language were normal. There were no cranial nerve abnormalities. He had marked dysarthria characterized by slow, strained speech with slurring of syllables. He had prominent spasticity in the lower limbs, predominantly involving the hamstrings and adductors. Upper limb spasticity was milder in degree. He had Grade 4 power in all the limbs along with exaggerated deep tendon reflexes, ankle and patellar clonus and extensor response to the plantar reflex on both sides. Sensory system examination was normal. There was no in-coordination or ataxia. Skull and spine were normal. Gait testing revealed a slow, spastic paraparetic gait with prominent scissoring, but he could walk unassisted. There were no neurocutaneous markers. Laboratory tests did not reveal any abnormalities in blood counts, electrolytes, renal, hepatic or thyroid functions. Vitamin B12 and erythrocyte folate levels were normal. Antiphospholipid, and anti-ds DNA antibodies were negative. He was negative for retroviral disease. Spinal and brain magnetic resonance imaging (MRI) was unremarkable. Nerve conduction study was normal, as were evoked potentials. Fundus and retina were normal. In view of the clinical presentation, consanguinity and multiple affected family members, genetic testing was offered to this family. Whole exome sequencing was offered to the proband and subsequently targeted sequencing using selective capture and sequencing of the protein coding regions of the genomes/genes were performed on the variant of interest in the remaining family members. Exon 9 of CAPN1 gene was PCR amplified and the product was sequenced using Sanger sequencing. The genetic study revealed the presence of a homozygous variant (c.1148 G > A; p.Gly383Asp) in CAPN1 gene, in the index patient. This variant was previously unreported in literature. Homozygous mutation in CAPN1 gene is known to cause HSP-76,[2] and hence this mutation is the most likely pathogenic variant in this family, thus confirming the diagnosis of HSP -76. Detailed evaluation of his relatives with history, clinical examination and genetic testing was done [Table 1].Table 1: Clinical data, age of onset and genetic testing results of the affected familyGan-Or et al.[2] (2016) reported 3 families, 2 consanguineous Moroccan families and 1 non-consanguineous North American family, with spastic paraplegia due to CAPN1 gene mutation. The clinical features of 8 patients were reported in detail. The average age at onset was 28.5 years (range 19 to 39); all affected individuals had spasticity and hyperreflexia of the lower limbs. Six patients had foot deformities, including pes cavus or pes valgus, 2 had abnormal bladder function, and 2 had distal sensory impairment. The motor impairment was mild to moderate, and 2 patients had started using a cane to aid in walking. There were no other neurologic abnormalities. The proband has a homozygous mutation along with his mother, maternal uncle and elder brother and are hence affected. The father and elder sister are heterozygous and unaffected. The patient's spouse was also evaluated for this pathogenic mutation and was found to be negative and hence progeny will not be affected. The current study is in concordance with previous studies that rare homozygous or compound-heterozygous mutations in CAPN1 cause a complicated form of HSP.[3] Most of the affected individuals from these families suffer from additional neurological symptoms in addition to the typical spasticity of the lower limbs, such as upper-extremity hyper-reflexia, dysarthria, and gait ataxia. CAPN1, located in chromosomal region 11q13, encodes calpain 1, also known as the large subunit of μ-calpain, a calcium-activated cysteine protease that is widely present in the CNS.[4] Calpain 1 is probably important for several functions in the CNS, but its exact role in humans is still not clear. Calpain 1 is involved in synaptic plasticity and several mechanisms for its function have been suggested in animal models.[5] For example, it was shown that Calpain interacts with CDK5 and NR2B to control NMDA-receptor degradation and synaptic plasticity.[6] However, there are contradicting results regarding the role of Calpains in neuroprotection and neurodegeneration, given that several studies suggest that calpain inhibition might be neuroprotective.[7] These features are also seen in other autosomal-recessive forms of HSP. For example, individuals with AR-HSP caused by mutations in SPG7 often present with phenotypes very similar to those described in the current study, including symptoms such as dysarthria, ataxia, upper-extremity hyperreflexia, amyotrophy, pes cavus, and sensory neuropathy.[89] HSP represents a heterogeneous group of diseases that may share a final common pathway in the neuronal degenerative process. This report presents a novel mutation in the CAPN1 gene, known to cause HSP 76. The phenotype of the affected individuals closely resembles that of a mild to moderate form of the disease with early onset and eventual plateauing. All patients in this family are on supportive and rehabilitative medical therapy and have mild to moderate morbidity and are living unassisted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Background: Neurological affection in Sjogren's syndrome (SS) can occur in the central and peripheral nervous system. Literature describing the neurological involvement in SS among Indian patients is lacking. Materials and Methods: Six patients of SS fulfilling the histological or serological criteria of the American European Consensus Group for SS were studied prospectively. The patients underwent clinical examination and laboratory investigations. Their clinical and investigation features are described. Results: The age of the patients ranged from 26 to 48 years, with a male to female ratio of 2:4. In our series, peripheral sensori-motor neuropathy and sensory ataxic neuropathy was seen in 3/6, mononeuritis multiplex in 2/6, cranial neuropathy in 2/6, autonomic neuropathy in 1/6, myelopathy in 4/6, optic neuropathy in 2/6, with presence of classical sicca features in 5/6 patients. Positive lip biopsy was seen in three, altitudinal field defect in one and positive Schirmer's test in five patients. Nerve conduction study abnormalities were seen in three and evidence of vasculitis was seen in nerve biopsy of one patient and chronic nonuniform axonopathy was seen in another. Antibody to Ro (SSA) or La (SSB) was positive in five patients. Conclusions: SS involves different parts of the nervous system with varied presentations. Clinical suspicion and adequate laboratory testing helps to diagnose and manage this disorder that is relatively rare in Indian patients.
Spontaneous subdural hematomas (SDH) are an unusual but potentially devastating complication of oral anticoagulation. Emergency management of subdural hematomas following oral anticoagulant therapy consists of reversal of anticoagulation coupled with surgical evacuation, if indicated. However, the question of reintroducing anticoagulants is a conundrum faced by clinicians. Clinical equipoise remains divergent among neurologists and literature guiding them is sparse. We report a case of spontaneous acute SDH in a middle-aged woman receiving dabigatran for cerebral venous thrombosis (CVT). Dabigatran reversal was achieved with idarucizumab and burr hole evacuation of the SDH was performed successfully. However, the patient suffered left posterior cerebral artery (PCA) territory ischemic stroke during this period, which appears to be a result of reversal of anticoagulant effect of dabigatran by idarucizumab. With this case report, we seek to highlight this rare complication of dabigatran therapy in CVT, the effectiveness of idarucizumab in reversing dabigatran action and the risks of interruption of dabigatran therapy with idarucizumab.
There are only a few studies describing the etiologic spectrum of biopsy-proven peripheral neuropathies in children. This study reviewed the clinical, electrophysiological, and pathologic profile of 239 children (≤18 years of age) who have undergone nerve biopsy in a tertiary care centre for neurologic disorders and analyzed the etiologic spectrum and utility of nerve biopsy. The clinical profile, neuropathologic findings, and other investigations were combined to infer the final diagnosis. Neuropathy was detected in 199 biopsies; axonal pathology in 43%; demyelination in 41%; mixed pattern in 8%; and nonspecific findings in 8%. The major diagnostic categories included hereditary neuropathies (48%), heredodegenerative and metabolic disorders (27%), and inflammatory neuropathies (12%). Nerve biopsy proved most helpful in diagnosis of demyelinating and inflammatory neuropathies, reiterating its usefulness in specific situations.
In-hospital strokes are a small but sizeable proportion of all strokes. Identification of in-hospital strokes is confounded by stroke mimics in as many as half of in-patient stroke codes. A quick scoring system based on risk factors and clinical signs during the initial evaluation of a suspected stroke might be helpful to distinguish true strokes from mimics. Two such scoring systems based on ischemic and hemorrhagic risk factors are the risk for in-patient stroke (RIPS) and the 2CAN score.This prospective clinical study was conducted at a quaternary care hospital in Bengaluru, India. All hospitalized patients aged 18 years and above for whom a "stroke code" alert was recorded during the study period of January 2019 to January 2020 were included in the study.A total of 121 in-patient "stroke codes" were documented during the study. Ischemic stroke was the most common etiological diagnosis. A total of 53 patients were diagnosed to have ischemic stroke, 4 had intracerebral hemorrhage, and the rest were mimics. Receiver operative curve analysis was performed and at a cut-off of RIPS ≥3, it predicts stroke with a sensitivity of 77% and a specificity of 73%. At a cut-off of 2CAN ≥3, it predicts stroke with a sensitivity of 67% and a specificity of 80%. RIPS and 2CAN significantly predicted stroke.There was no difference in the use of either RIPS or 2CAN for differentiating stroke from mimics, and hence they may be used interchangeably. They were statistically significant with good sensitivity and specificity, as a screening tool to determine in-patient stroke.